Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Valneva (VALN)
NASDAQ:VALN
Holding VALN?
Track your performance easily
VALN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.62 - $9.50
Previous CloseN/A
Volume18.63K
Average Volume (3M)55.95K
Market Cap
$357.42M
Enterprise Value$539.83M
Total Cash (Recent Filing)$35.27M
Total Debt (Recent Filing)$61.54M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Mar 20, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding81,260,765
10 Day Avg. Volume38,478
30 Day Avg. Volume55,951
Standard Deviation0.24
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.07
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue2.37
Enterprise Value/Gross Profit10.22
Enterprise Value/Ebitda-8.29
Forecast
1Y Price Target
$12.70Price Target Upside190.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Valneva News
PremiumCompany Announcements
Valneva Engages Investors at J.P. Morgan Healthcare Conference
PremiumCompany Announcements
Valneva Highlights Chikungunya’s Global Economic Impact
PremiumCompany Announcements
Valneva’s Chikungunya Vaccine Shows Long-Lasting EfficacyPremiumCompany Announcements
Valneva Seeks FDA Approval for Expanded Vaccine Use
PremiumCompany Announcements
Valneva Engages Investors with Promising Vaccine Developments
PremiumCompany Announcements
Valneva SE Reports Profitable Nine-Month PerformanceBulls Say, Bears Say
Bulls Say
Funding And Financial SupportValneva received a new grant from the Coalition for Epidemic Preparedness Innovations, providing up to $41.3M of additional funding over the next five years in support of Phase 4 costs and other studies.
Regulatory And Commercial MilestonesAn ongoing Phase 3 pivotal study in Lyme disease is expected to be completed by YE25, and Pfizer is expected to submit a BLA to the FDA and an MAA to the EMA in 2026 if data from the trial are positive.
Vaccine Development And Market PotentialThe Lyme disease vaccine is a potential blockbuster with ongoing Phase 3 trials targeting a global market opportunity well over $1B.
Bears Say
Debt MaturityReimbursements of the second tranche of $100M are to start in 1Q27 and mature in 4Q28.
Financial ObligationsReimbursements of the first $100M tranche are to start in January 2026 and mature in 1Q27.
Sales PerformanceIxchiq sales ramp slower than forecast, impacting overall expectations.
---
Ownership Overview
―
Insiders
0.15%
Mutual Funds
<0.01% Other Institutional Investors
99.85% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VALN FAQ
What was Valneva’s price range in the past 12 months?
Valneva lowest stock price was $3.62 and its highest was $9.50 in the past 12 months.
What is Valneva’s market cap?
Valneva’s market cap is $357.42M.
When is Valneva’s upcoming earnings report date?
Valneva’s upcoming earnings report date is Mar 20, 2025 which is in 58 days.
How were Valneva’s earnings last quarter?
Valneva released its earnings results on Nov 07, 2024. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.266 by $0.156.
Is Valneva overvalued?
According to Wall Street analysts Valneva’s price is currently Undervalued.
Does Valneva pay dividends?
Valneva does not currently pay dividends.
What is Valneva’s EPS estimate?
Valneva’s EPS estimate is -0.19.
How many shares outstanding does Valneva have?
Valneva has 81,260,765 shares outstanding.
What happened to Valneva’s price movement after its last earnings report?
Valneva reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.266. Following the earnings report the stock price went down -1.968%.
Which hedge fund is a major shareholder of Valneva?
Currently, no hedge funds are holding shares in VALN
---
Valneva Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.70 (190.62% Upside)
$12.70 (190.62% Upside)
Blogger Sentiment
Bullish
VALN Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.4%
Last 30 Days ▲ 18.2%
Last 30 Days ▲ 18.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.81%
12-Months-Change
Fundamentals
Return on Equity
-3.73%
Trailing 12-Months
Asset Growth
4.62%
Trailing 12-Months
Company Description
Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally.
---
VALN Company Deck
---
VALN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with strong financial performance, significant progress in vaccine development, particularly for chikungunya and Lyme disease, and an extended cash runway. However, supply constraints affected IXIARO sales, and there were declines in third-party sales, along with higher costs affecting margins.Read More>---
VALN Stock 12 Month Forecast
Average Price Target
$12.70
▲(190.62% Upside)
Technical Analysis
Best Analysts Covering VALN
1 Year
1 Year Success Rate
0/22 ratings generated profit
1 Year Average Return
-36.90%
reiterated a buy rating 2 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.90% per trade.
---